Sonic Healthcare AI Stock Analysis
Want to see SKHHY full AI Analyst Report?
Sonic Healthcare (SKHHY) AI Stock Analysis
Sonic Healthcare
(Other OTC:SKHHY)
Overall score is driven primarily by solid but not standout financial performance (strong growth, moderated margins/returns, and weaker cash conversion) and a constructive earnings-call backdrop tempered by meaningful near-term headwinds and conservative guidance. Valuation helps notably thanks to a strong dividend yield and reasonable P/E, while technical indicators are mixed with modest momentum but some near-term softness.
Sonic Healthcare (SKHHY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $6.66B
- Dividend Yield
- 5.70%
- Average Volume (3M)
- 114.09K
- Price to Earnings (P/E)
- 16.1
- Beta (1Y)
- 0.41
- Revenue Growth
- 19.96%
- EPS Growth
- 21.43%
- Country
- US
- Employees
- 49,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Sonic Healthcare Business Overview & Revenue Model
Company Description
Headquartered in Sydney, Australia, Sonic Healthcare Limited, established in 1934, is a global provider of medical diagnostic and healthcare services. The company delivers a comprehensive range of laboratory medicine (pathology) services, alongside e...
How the Company Makes Money
Sonic Healthcare primarily makes money by delivering diagnostic services and receiving payment for each service performed. Its two main revenue streams are: (1) Pathology/Laboratory services: revenue is generated from clinical laboratory tests such a...
Sonic Healthcare Earnings Call Summary
The call conveyed a predominantly positive performance picture: strong revenue, EBITDA and NPAT growth, solid organic expansion, and notable success in advanced diagnostics and M&A integration (notably Germany and Switzerland). Management also outlined proactive investments in digital transformation and clear U.S. turnaround actions expected to deliver AUD 25–30 million in FY2027 earnings. However, several near-term headwinds were emphasized, including regulatory fee cuts in Switzerland (CHF 20m), U.K. contract integration delays, software impairments and legacy IT write-downs, higher interest and capex in FY2026, FX and policy uncertainties (PAMA, GOÄ). On balance the highlights (growth, synergy capture, digital investment and disciplined capital management) outweigh the lowlights, although they limit near-term upside and keep guidance conservative.
Q4-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Guidance for FY2027 is for constant‑currency EBITDA of AUD 1.95–2.03 billion (note this excludes ~AUD 30 million of back‑office IT transformation costs), with depreciation forecast at AUD 810–825 million, amortisation AUD 90–95 million, interest expense expected to rise ~6% versus FY2026 and an effective tax rate of ~27%; the guidance assumes only completed acquisitions, no future regulatory changes (PAMA fee cuts excluded), current interest rates and excludes any property sale gains. Management expects the U.S. operating review to contribute c. AUD 25–30 million to FY2027 earnings, while a Swiss regulatory fee change is estimated to reduce FY2027 revenue by CHF 20 million (≈3% of Swiss revenue); foreign‑exchange movements at current spot rates could imply a c. AUD 40–50 million headwind to group EBITDA. Capital discipline remains a priority: maintenance CapEx is around 3% of revenue (FY2026 maintenance CapEx ~AUD 351 million), property‑related CapEx is expected to fall from FY2028 levels, the medium‑term dividend payout target is 70–80% of net profit (FY2026 full‑year dividend AUD 1.08, final AUD 0.63, 60% franked), and balance‑sheet metrics include a FY2026 net debt cover ratio of 2.2 and available headroom of ~AUD 1.6 billion pre‑dividend.
Sonic Healthcare Financial Statement Overview
Summary
Income statement shows strong recent revenue momentum but only mid-single-digit margins and profitability well below prior peak years. Balance sheet is supported by substantial equity, though leverage has risen (debt-to-equity trending up) and ROE has cooled. Cash flow remains positive, but cash conversion has weakened (operating cash flow and free cash flow running below net income in recent years), adding inconsistency risk.
Income Statement
64PositiveBalance Sheet
62PositiveCash Flow
57Neutral| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.93B | 10.71B | 9.65B | 8.93B | 7.96B | 9.31B |
| Gross Profit | 3.03B | 2.96B | 3.19B | 2.94B | 2.11B | 3.41B |
| EBITDA | 1.95B | 1.91B | 1.75B | 1.63B | 1.72B | 2.80B |
| Net Income | 608.36M | 595.00M | 513.60M | 511.09M | 684.98M | 1.46B |
Balance Sheet | ||||||
| Total Assets | 16.78B | 16.78B | 16.05B | 14.83B | 13.56B | 13.11B |
| Cash, Cash Equivalents and Short-Term Investments | 653.73M | 653.73M | 673.77M | 645.00M | 797.99M | 780.00M |
| Total Debt | 5.84B | 5.84B | 5.17B | 4.52B | 3.10B | 3.01B |
| Total Liabilities | 8.29B | 8.29B | 7.58B | 6.75B | 5.64B | 5.68B |
| Stockholders Equity | 8.34B | 8.34B | 8.32B | 7.92B | 7.74B | 7.27B |
Cash Flow | ||||||
| Free Cash Flow | 798.37M | 757.78M | 960.55M | 492.01M | 974.02M | 1.85B |
| Operating Cash Flow | 1.45B | 1.37B | 1.30B | 1.07B | 1.47B | 2.23B |
| Investing Cash Flow | -944.23M | -877.39M | -577.62M | -1.81B | -580.04M | -989.18M |
| Financing Cash Flow | -512.69M | -500.78M | -735.93M | 592.41M | -911.51M | -1.35B |
Sonic Healthcare Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SKHHY, the sentiment is Negative. The current price of 13.48 is below the 20-day moving average (MA) of 13.48, above the 50-day MA of 13.41, and below the 200-day MA of 14.02, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 49.81 is Neutral, neither overbought nor oversold. The STOCH value of 1.32 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SKHHY.
Sonic Healthcare Peers Comparison
Overall Rating
DGX76Outperform
LH75Outperform
NEO68Neutral
SKHHY64Neutral
RDNT55Neutral
GH44.3Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 76Outperform | $28.56B | 25.50 | 15.21% | 1.30% | 9.13% | 17.93% | |
| 75Outperform | $30.08B | 30.19 | 11.54% | 0.78% | 6.02% | 19.63% | |
| 68Neutral | $2.07B | -64.91 | -3.97% | ― | 11.08% | 71.76% | |
| 64Neutral | $6.65B | 16.14 | 7.20% | 5.70% | 19.96% | 21.43% | |
| 55Neutral | $6.02B | -265.53 | -2.04% | ― | 21.06% | -70.26% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | $20.52B | -41.22 | 249.03% | ― | 41.69% | -14.59% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SKHHY | Sonic Healthcare Limited | 13.48 | 0.45 | 3.45% | |
| LH | Labcorp Holdings Inc. | 370.48 | 111.73 | 43.18% | |
| DGX | Quest Diagnostics | 259.60 | 76.49 | 41.77% | |
| RDNT | Radnet | 76.42 | -0.62 | -0.80% | |
| NEO | NeoGenomics Inc. | 16.02 | 5.80 | 56.75% | |
| GH | Guardant Health | 151.70 | 55.22 | 57.23% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 22, 2026
